LSPedia 的全球序列化系列
序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.png)
欢迎来到 LspEdia,在这里,创新与奉献精神相结合。
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。

序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。
As global trade tensions rise, pharmaceutical manufacturers and supply chain stakeholders face new challenges—and new risks. The U.S. government has signaled renewed focus on tariffs targeting key markets, and the ripple effects could be significant across the pharma landscape.
In a recent discussion featuring Ryan Kelly (Senior Director, Supply Chain Security & Brand Protection, Rx-360), Riya Cao (CEO, LSPedia), Daniel MacKinnon (SVP of Sales & Marketing, LSPedia) and Rose Campasano (VP of Industry Relations, LSPedia) , the conversation turned toward the intersection of tariffs, sourcing risk, serialization, and how the industry can prepare for what’s ahead.
Tariffs Are Here to Stay—and Pharma Must Be Ready
“We don’t really know where the tariffs are going to end up... but we can probably be very certain to say there will be tariffs. And it’s not something that can go away quickly.”
— Riya Cao, CEO, LSPedia
Tariffs introduce new cost pressures, prompting pharmaceutical companies to reassess sourcing strategies and supply chain structures. However, these changes often create new vulnerabilities—particularly around the introduction of substandard or falsified products.
“Anytime we see price increases, we see an increase in bad actors... threats of illicit materials and falsified medicines.”
— Ryan Kelly, Rx-360
As companies adjust to the economic realities of tariffs, safeguards like serialization and verification become more essential than ever. These tools aren’t just about regulatory compliance—they’re about protecting product integrity and patient safety.
Cost Pressures Can Open the Door to Counterfeits
As prices rise, the temptation to find cheaper alternatives can be risky. Lower prices may come with tradeoffs in quality, authenticity, or legality. The risk of counterfeit or diverted drugs entering the supply chain increases substantially when alternative sourcing is pursued without proper controls.
“With increased tariffs, organizations are going to respond. But as they respond, it really needs a keen eye on making sure any prices that are too good to be true, potentially are.”
— Ryan Kelly, Rx-360
This is where serialization becomes a strategic asset. DSCSA-compliant platforms like LSPedia’s OneScan provide traceability and real-time verification that help identify anomalies—such as diverted product or labeling issues—before they reach patients.
Beyond Compliance: Serialization as a Business Driver
“Why not track active pharmaceutical ingredients? Why not track other materials in the same system?”
— Riya Cao, LSPedia
Historically, serialization has focused on finished goods. But in the face of tariff-driven sourcing changes, it’s increasingly valuable to apply serialization tools to raw materials, APIs, and other upstream components. LSPedia customers are using OneScan to gain visibility across their entire supply chain—not just for compliance, but for better business intelligence.
From reverse logistics to alternative sourcing analysis, serialization data is proving to be an asset far beyond the scope of regulation. When used strategically, it helps reduce risk, improve transparency, and support growth—even in challenging market conditions.
Key Takeaways for Pharma Stakeholders
Final Thoughts
Tariffs aren’t just a policy headline—they’re a supply chain reality. Companies that are proactive in adapting their operations and using available tools like OneScan will be better equipped to protect product quality, remain compliant, and respond to global disruptions with confidence.
To learn more about how LSPedia helps manufacturers, CMOs, and dispensers strengthen their supply chain through serialization and exception management, contact us today.